Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 17, 2021 - Issue 11
Submit an article Journal homepage
2,149
Views
0
CrossRef citations to date
0
Altmetric
Editorial

How suitable is intravenous tocilizumab for the treatment of Graves’ ophthalmopathy?

Maria Alejandra Mejía Gonzáleza Immunology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain;b Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
&
Javier Carbonea Immunology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain;b Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain;c Immunology, Ophthalmology and ENT Department, Universidad Complutense, Madrid, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2056-0534
ORCID Icon
Pages 1151-1153 | Received 30 Aug 2021, Accepted 22 Oct 2021, Published online: 01 Nov 2021

References

  • Hamed Azzam S, Kang S, Salvi M, et al. Tocilizumab for thyroid eye disease. Cochrane Database Syst Rev. 2018;11(11):CD012984. Published 2018 Nov 27.
  • Taylor PN, Zhang L, Lee RWJ, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol. 2020 Feb;16(2):104–116. Epub 2019 Dec 30. PMID: 31889140.
  • Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ Orbitopahy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Rev Eur J Endocrinol. 2021. Online ahead of print. DOI: https://doi.org/10.1530/EJE-21-0479.
  • Fallahi P, Ferrari SM, Elia G, et al. Cytokines as targets of novel therapies for Graves’ ophthalmopathy. Rev Front Endocrinol (Lausanne). 2021;12:654473.
  • Łacheta D, Miśkiewicz P, Głuszko A, et al. Immunological aspects of Graves’ ophthalmopathy. Biomed Res Int. 2019;2019:7453260.
  • Hong Lee AC, Kahaly GJ. Novel approaches for immunosuppression in Graves’ hyperthyroidism and associated orbitopathy. Eur Thyroid J. 2020;9(Suppl1):17–30. Epub 2020 Aug 10.
  • Dik WA, Virakul S, van Steensel L. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves’ ophthalmopathy. Exp Eye Res. 2016;142:83–91.
  • Pérez-Moreiras JV, Varela-Agra M, Prada-Sánchez MC, et al. Steroid-resistant Graves’ orbitopathy treated with tocilizumab in real-world clinical practice: a 9-year single-center experience. J Clin Med. 2021;10(4):706.
  • Sánchez-Bilbao L, Martínez-López D, Revenga M, et al. Anti-IL-6 receptor tocilizumab in refractory Graves’ orbitopathy: national multicenter observational study of 48 patients. J Clin Med. 2020;9(9):2816.
  • Bennedjaï A, Bouheraoua N, Gatfossé M, et al. Tocilizumab versus rituximab in patients with moderate to severe steroid-resistant Graves’ orbitopathy. Ocul Immunol Inflamm. 2020:1–6. Online ahead of print. DOI:https://doi.org/10.1080/09273948.2020.1808688.
  • Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al.; Tocilizumab in Graves Orbitopathy Study Group. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018;195:181–190. PMID: 30081019 Clinical Trial.
  • Leszczynska A, Molins B, Fernández E, et al. Cytokine production in thyroid eye disease: in vitro effects of dexamethasone and IL-6 blockade with tocilizumab. Graefes Arch Clin Exp Ophthalmol. 2019;257(10):2307–2314.
  • Barbieri MA, Cicala G, Cutroneo PM, et al. Safety profile of biologics used in rheumatology: an italian prospective pharmacovigilance study. J Clin Med. 2020;9(4):1227.
  • Tocilizumab shortage continues as pandemic wears on. [cited 2021 Aug 29]. Available from: https://www.medscape.com/viewarticle/956882
  • Silkiss RZ, Paap MK, Roelofs KA, et al. Treatment of corticosteroid-resistant thyroid eye disease with subcutaneous tocilizumab. Can J Ophthalmol. 2021;56(1):66–70.
  • Copperman T, Idowu OO, Kersten RC, et al. Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery. Ophthalmic Plast Reconstr Surg. 2019;35(3):e64–e66.
  • Kahaly GJ, Douglas RS, Holt RJ, et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 2021;9(6):360–372.
  • Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341–352.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.